Moderna (MRNA) Q1 2026 earnings review
Strong Revenue Rebound Masked by Massive Litigation Charge
Moderna delivered a solid start to 2026 with $389 million in total revenue (+260% YoY), driven by international deliveries. However, an $878 million litigation settlement with Arbutus pushed the GAAP net loss to $1.34 billion. Excluding this one-time hit, underlying financials show significant progress: adjusted net loss narrowed by 52% YoY to $465 million as R&D and SG&A expenses decelerated rapidly. Management reaffirmed 2026 guidance for up to 10% revenue growth and targeted year-end cash of $4.5–$5.0 billion, pointing to an accelerating commercial transformation with recent EU approvals for its flu/COVID combination vaccine.
🐂 Bull Case
Moderna's aggressive operational restructuring is visible. Excluding the litigation charge, underlying 26Q1 adjusted cash costs dropped 26% YoY, proving management can right-size the business while the pipeline matures.
The EU approval of mCOMBRIAX (flu + COVID) and mNEXSPIKE validates the pipeline and sets the stage for a strong European market capture starting in 2027.
🐻 Bear Case
The $878 million Arbutus settlement payment due in Q3 represents roughly 20% of the company's projected year-end cash, significantly reducing the financial buffer to reach 2028 cash flow breakeven.
The U.S. FDA path for the flu + COVID combination remains stalled as the company awaits further guidance on refiling, threatening its ability to compete in its highest-margin geography.
⚖️ Verdict: ⚪
Neutral. The underlying operational turnaround and aggressive expense reductions are exactly what investors want to see. However, the $878 million litigation payout is a massive near-term cash drain that leaves little room for error over the next two years.
Key Themes
The Arbutus Settlement Cash Drain
While removing the legal overhang of the Arbutus IP litigation is a long-term positive, the $878 million settlement (payable in 26Q3) is a massive blow to the balance sheet. It drastically reduces their margin of error for reaching their 2028 cash flow breakeven target. Cash and investments are now guided to drop to $4.5–$5.0 billion by year-end, down from $8.1 billion just three months ago.
Expense Reduction is Accelerating
The company's aggressive cost-cutting measures are clearly flowing to the bottom line. Q1 R&D dropped 24% YoY to $649M (driven by the wind-down of large Phase 3 respiratory and CMV trials), and SG&A fell 18% YoY to $173M. Excluding the litigation charge, cost of sales actually declined 14%. This strict financial discipline is the core driver keeping the company afloat.
Regulatory Wins for Respiratory Portfolio
Moderna achieved a major commercial milestone with European approvals for mNEXSPIKE and mCOMBRIAX (the world's first flu + COVID combination vaccine). Capturing the European market is a critical driver for their multi-year revenue growth strategy, and these approvals clear the primary hurdle for international adoption.
U.S. Flu Regulatory Uncertainty Remains
Despite the success in the EU, the U.S. regulatory path contradicts the positive global narrative. While the standalone flu vaccine (mRNA-1010) has an August 5, 2026 PDUFA date, management is still 'awaiting further guidance' from the U.S. FDA on refiling the submission for its flu plus COVID combination vaccine. This delay risks ceding early U.S. market share to competitors.
Intismeran and the Oncology Franchise
Moderna's technology pivot toward oncology is accelerating. They initiated a new Phase 3 trial for Intismeran (mRNA-4157) in high-risk Stage 1 non-small cell lung cancer (NSCLC). Furthermore, upcoming 5-year Phase 2b data at ASCO for Intismeran plus KEYTRUDA in adjuvant melanoma will be a major catalyst, moving the company beyond its pandemic legacy.
Seasonal Macro Reliance and H2 Weighting
Revenue remains extremely lopsided. With Q1 revenue at $389M and H1 total guidance of $0.4B-$0.5B, the company is relying almost entirely on H2 for the remaining ~$1.6B of its 2026 target. This deep seasonality leaves the company highly vulnerable to shifting fall vaccination trends, macro consumer behavior, and competitive pricing dynamics.
Other KPIs
Reversing. Up 260% YoY from $108 million. Roughly 80% ($311 million) came from international markets, successfully validating management's strategy to lean on long-term international supply agreements to offset U.S. market declines.
Decelerating. Down 24% YoY from $856 million in 25Q1. The drop reflects the successful completion and wind-down of massive Phase 3 respiratory and congenital CMV studies, allowing capital reallocation toward the oncology pipeline.
Accelerating improvement. When stripping out the $878 million litigation charge, the underlying net loss improved dramatically by 52% from $(971) million a year ago. This highlights the real impact of the company's organizational restructuring.
Guidance
Stable. Maintained from prior guidance. Applying up to 10% growth to FY25's $1.9 billion implies ~$2.1 billion. The growth is heavily dependent on international deliveries and the anticipated launch of newly approved respiratory products in the second half of the year.
Accelerating. This includes the one-time $0.9 billion litigation charge. Excluding this, the underlying cost of sales guidance implies ~$0.9 billion, representing a significant YoY margin improvement on a base of higher expected revenue.
Decelerating. Downward revision from prior trajectory solely to absorb the $950 million litigation payment. This leaves a relatively tight buffer for a company burning cash in operations, making the 2028 cash flow breakeven timeline critical.
Key Questions
Arbutus Settlement Impact on Capital Allocation
With the $878 million Arbutus settlement hitting cash reserves in Q3, does this alter your timeline or confidence in achieving cash flow breakeven by 2028 without needing to tap equity markets or draw further on the credit facility?
U.S. FDA Combo Vaccine Hurdles
You noted that you are 'awaiting further guidance' from the FDA regarding the flu + COVID combination vaccine refiling. What specific clinical or manufacturing hurdles remain, and is a 2027 U.S. launch still viable?
European Market Capture Dynamics
How is the rollout of mCOMBRIAX in Europe structured for the upcoming fall season, and what specific market share assumptions are baked into your H2 revenue guidance?